Orphan drugs continue to dominate the novel agents clearing the FDA Center for Drug Evaluation and Research in 2022. The approval of Marinus Pharmaceuticals, Inc.’s Ztalmy marked the fourth consecutive orphan-designated novel approval, and brings the year-to-date count to five orphans out of the eight new molecular entities and novel biologics approved by CDER.
A new adjuvant breast cancer indication for AstraZeneca PLC/Merck & Co., Inc.’s Lynparza illustrated the movement of newer...






